{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:22:52Z","timestamp":1792765372493,"version":"4.5.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>A recent consensus guideline recommends migrating the therapeutic drug monitoring practice for intravenous vancomycin for the treatment of methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> infection from the traditional trough-based approach to the Bayesian approach based on area under curve to improve clinical outcomes. To support the implementation of the new strategy for hospitals under Hospital Authority, Hong Kong, this study is being proposed to (1) estimate and validate a population pharmacokinetic model of intravenous vancomycin for local adults, (2) develop a web-based individual dose optimization application for clinical use, and (3) evaluate the performance of the application by comparing the treatment outcomes and clinical satisfaction against the traditional approach. 300 adult subjects prescribed with intravenous vancomycin and not on renal replacement therapy will be recruited for population pharmacokinetic model development and validation. Sex, age, body weight, serum creatinine level, intravenous vancomycin dosing records, serum vancomycin concentrations <jats:italic>etc<\/jats:italic>. will be collected from several electronic health record systems maintained by Hospital Authority. Parameter estimation will be performed using non-linear mixed-effect modeling techniques. The web-based individual dose optimization application is based on a previously reported application and is built using R and the package <jats:italic>shiny<\/jats:italic>. Data from another 50 subjects will be collected during the last three months of the study period and treated as informed by the developed application and compared against historical control for clinical outcomes. Since the study will incur extra blood-taking procedures from patients, informed consent is required. Other than that, recruited subjects should receive medical treatments as usual. Identifiable patient data will be available only to site investigators and clinicians in each hospital. The study protocol and informed consent forms have been approved by the Joint Chinese University of Hong Kong\u2013New Territories East Cluster Clinical Research Ethics Committee (reference number: NTEC-2021-0215) and registered at the Chinese Clinical Trial Registry (registration number: ChiCTR2100048714).<\/jats:p>","DOI":"10.1371\/journal.pone.0267894","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T17:36:47Z","timestamp":1651772207000},"page":"e0267894","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multi-center prospective population pharmacokinetic study and the performance of web-based individual dose optimization application of intravenous vancomycin for adults in Hong Kong: A study protocol"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0950-8524","authenticated-orcid":true,"given":"Ka Ho Matthew","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-2967","authenticated-orcid":true,"given":"Chung Yan Grace","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Lun Alan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin Ting","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7259-4050","authenticated-orcid":true,"given":"Tai Ning Teddy","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"issue":"3","key":"pone.0267894.ref001","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"C Liu","year":"2011","journal-title":"Clinical Infectious Diseases"},{"issue":"11","key":"pone.0267894.ref002","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysis","volume":"69","author":"DM Aljefri","year":"2019","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"pone.0267894.ref003","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1177\/106002809402801201","article-title":"Impact of vancomycin therapeutic drug monitoring on patient care","volume":"28","author":"TE Welty","year":"1994","journal-title":"Annals of Pharmacotherapy"},{"issue":"1","key":"pone.0267894.ref004","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"M Rybak","year":"2009","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"11","key":"pone.0267894.ref005","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"MJ Rybak","year":"2020","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"1","key":"pone.0267894.ref006","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"MN Neely","year":"2014","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"2","key":"pone.0267894.ref007","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijantimicag.2013.10.017","article-title":"Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia","volume":"43","author":"Y Jung","year":"2014","journal-title":"International journal of antimicrobial agents"},{"issue":"2","key":"pone.0267894.ref008","doi-asserted-by":"crossref","first-page":"e02042","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing","volume":"62","author":"MN Neely","year":"2018","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"4","key":"pone.0267894.ref009","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000343162","article-title":"Is Peak Concentration Needed in Therapeutic Drug Monitoring of Vancomycin? A Pharmacokinetic-Pharmacodynamic Analysis in Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia","volume":"58","author":"Y Suzuki","year":"2012","journal-title":"Chemotherapy"},{"issue":"1","key":"pone.0267894.ref010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12911-014-0128-0","article-title":"A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children","volume":"15","author":"AK Hamberg","year":"2015","journal-title":"BMC medical informatics and decision making"},{"issue":"6","key":"pone.0267894.ref011","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/FTD.0000000000000206","article-title":"Excel-based tool for pharmacokinetically guided dose adjustment of paclitaxel","volume":"37","author":"S Kraff","year":"2015","journal-title":"Therapeutic drug monitoring"},{"key":"pone.0267894.ref012","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.ejps.2017.05.037","article-title":"Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies","volume":"109","author":"T Mizuno","year":"2017","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"pone.0267894.ref013","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40262-018-00732-2","article-title":"Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin","volume":"58","author":"SW van Beek","year":"2019","journal-title":"Clinical pharmacokinetics"},{"issue":"1","key":"pone.0267894.ref014","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40262-012-0020-y","article-title":"Benchmarking Therapeutic Drug Monitoring Software: A Review of Available Computer Tools","volume":"52","author":"A Fuchs","year":"2013","journal-title":"Clinical Pharmacokinetics"},{"issue":"6","key":"pone.0267894.ref015","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10096-012-1811-7","article-title":"Correlation of methicillin-resistant Staphylococcus aureus vancomycin minimal inhibitory concentration results by Etest and broth microdilution methods with population analysis profile: lack of Etest overestimation of the MIC","volume":"32","author":"R Khatib","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"pone.0267894.ref016","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.2006.02725.x","article-title":"Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance","volume":"63","author":"BJ Anderson","year":"2007","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"6","key":"pone.0267894.ref017","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF01113502","article-title":"The importance of modeling interoccasion variability in population pharmacokinetic analyses","volume":"21","author":"MO Karlsson","year":"1993","journal-title":"Journal of Pharmacokinetics and Biopharmaceutics"},{"issue":"6","key":"pone.0267894.ref018","first-page":"1","article-title":"Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose","volume":"2","author":"RJ Keizer","year":"2013","journal-title":"CPT: pharmacometrics & systems pharmacology"},{"key":"pone.0267894.ref019","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.ejps.2017.05.056","article-title":"Allometric size: The scientific theory and extension to normal fat mass","volume":"109S","author":"NHG Holford","year":"2017","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"1","key":"pone.0267894.ref020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of Creatinine Clearance from Serum Creatinine","volume":"16","author":"DW Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"2","key":"pone.0267894.ref021","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.2041-210X.2010.00063.x","article-title":"A unified approach to model selection using the likelihood ratio test","volume":"2","author":"F Lewis","year":"2011","journal-title":"Methods in Ecology and Evolution"},{"issue":"2","key":"pone.0267894.ref022","first-page":"87","article-title":"Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics","volume":"6","author":"TH Nguyen","year":"2017","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"1","key":"pone.0267894.ref023","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10928-013-9343-z","article-title":"Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effect models: a simulation study in population pharmacokinetics","volume":"41","author":"HT Thai","year":"2014","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"key":"pone.0267894.ref024","volume-title":"NONMEM Users Guides","author":"AJ Boeckmann","year":"2009"},{"issue":"4","key":"pone.0267894.ref025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","article-title":"Likelihood based approaches to handling data below the quantification limit using NONMEM VI","volume":"35","author":"JE Ahn","year":"2008","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"3","key":"pone.0267894.ref026","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"L Lindbom","year":"2005","journal-title":"Computer Methods and Programs in Biomedicine"},{"key":"pone.0267894.ref027","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2020"},{"key":"pone.0267894.ref028","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"H. Wickham","year":"2016"},{"issue":"4","key":"pone.0267894.ref029","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/jcph.1349","article-title":"Population Pharmacokinetic Study and Individual Dose Adjustments of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia or Osteosarcoma","volume":"59","author":"KH Hui","year":"2019","journal-title":"Journal of Clinical Pharmacology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0267894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T17:37:20Z","timestamp":1651772240000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0267894"}},"subtitle":[],"editor":[{"given":"Steven Eric","family":"Wolf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0267894","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]}}}